Coupled D dimer and fibrinogen levels during thrombolytic therapy of venous thromboembolism.
Jude
B
B
Laboratoire d'hématologie, Hôpital Cardiologique, Lille, France.
Amrouni
N
N
Deguine
I
I
Marey
A
A
Asseman
P
P
Watel
A
A
Thery
C
C
Marache
P
P
Cosson
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005340:Fibrinogen / Q000032:analysis*; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use; D010958:Plasminogen / Q000627:therapeutic use; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013924:Thrombophlebitis / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; C036309:fibrin fragment D; C018998:lysyl-plasminogen; D005340:Fibrinogen; D010958:Plasminogen; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator